Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6578159 | 0.98 | ALDH1A1 (0.55) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL23007584 | 0.95 | ALDH1A1 (0.48) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL18573883 | 0.91 | CYP1A2 (0.44) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL4577419 | 0.89 | GAA (0.44) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL6575839 | 0.88 | ALDH1A1 (0.47) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL6099264 | 0.87 | LMNA (0.44) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL7848700 | 0.87 | GAA (0.46) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL11417985 | 0.84 | GAA (0.40) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL466237 | 0.83 | ALDH1A1 (0.50) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL5592415 | 0.83 | ALDH1A1 (0.50) | ALDH1A1CYP1A2USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007120485-A2 | METHODS OF TREATING PAIN WITH ALKYLXANTHINES AND ANTIEPILEPTICS AND COMPOSITIONS FOR USE THEREFOR | CINERGEN, LLC (US) | 2007-10-25 | — | — | WO | claimed |
| EP-0552240-B1 | NEW METHOD OF TREATING DEPRESSION | WARNER LAMBERT CO (US) | 1998-03-18 | — | — | EP | claimed |
| EP-0446570-B1 | Gabapentin and its derivatives for treating neurodegenerative diseases | WARNER LAMBERT CO (US) | 1995-08-02 | — | — | EP | claimed |
| EP-0458751-A1 | Delivery system for cyclic amino acids with improved taste, texture and compressibility | WARNER-LAMBERT COMPANY (US) | 1991-11-27 | — | — | EP | claimed |
| US-4087544-A | Treatment of cranial dysfunctions using novel cyclic amino acids | WARNER-LAMBERT COMPANY (US) | 1978-05-02 | — | — | US | claimed |
| US-4024175-A | Cyclic amino acids | WARNER-LAMBERT COMPANY (US) | 1977-05-17 | — | — | US | claimed |
| WO-2023115167-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| US-20230150922-A1 | Fluorinated Derivatives of Gabapentin and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-18 | — | — | US | disclosed |
| WO-2021216753-A1 | FLUORINATED DERIVATIVES OF GABAPENTIN AND METHODS OF USE THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2021-10-28 | — | — | WO | disclosed |
| US-8357723-B2 | Prodrugs containing novel bio-cleavable linkers | Piramal Enterprises Limited and Apparao Satyam (IN) | 2013-01-22 | — | — | US | disclosed |
| US-8354455-B2 | Prodrugs containing novel bio-cleavable linkers | Piramal Enterprises Limited and Apparao Satyam (IN) | 2013-01-15 | — | — | US | disclosed |
| US-8349901-B2 | Prodrugs containing novel bio-cleavable linkers | Piramal Enterprises Limited and Apparao Satyam (IN) | 2013-01-08 | — | — | US | disclosed |
| WO-2012164055-A2 | NEW COMPOUNDS, SYNTHESIS AND USE THEREOF IN THE TREATMENT OF PAIN | LACER, S.A. (ES) | 2012-12-06 | — | — | WO | disclosed |
| US-5091567-A | Reacting cyclohexanone with phosphonoacetic acid ester, condensing with nitromethane, reducing, hydrolyzing | GODECKE AKTIENGESELLSCHAFT (DE) | 1992-02-25 | — | — | US | disclosed |
| US-5084479-A | Aminomethylcycloalkylacetic acids for nervous system disorders | WARNER-LAMBERT COMPANY (US) | 1992-01-28 | — | — | US | disclosed |
| EP-0458751-A1 | Delivery system for cyclic amino acids with improved taste, texture and compressibility | WARNER-LAMBERT COMPANY (US) | 1991-11-27 | — | — | EP | disclosed |
| EP-0446570-A2 | Gabapentin and its derivatives for treating neurodegenerative diseases | WARNER-LAMBERT COMPANY (US) | 1991-09-18 | — | — | EP | disclosed |
| US-5025035-A | Administering antidepressants | WARNER-LAMBERT COMPANY (US) | 1991-06-18 | — | — | US | disclosed |
| US-4087544-A | Treatment of cranial dysfunctions using novel cyclic amino acids | WARNER-LAMBERT COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-4024175-A | Cyclic amino acids | WARNER-LAMBERT COMPANY (US) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150922-A1 | Fluorinated Derivatives of Gabapentin and Methods of Use Thereof | GABRE, GABBR1, GABRB3 | ALDH1A1 1279/4885CYP1A2 1530/4885USP2 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.